Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer.

Tőkés T, Tőkés AM, Szentmártoni G, Kiszner G, Mühl D, Molnár BÁ, Kulka J, Krenács T, Dank M.

Pathol Oncol Res. 2019 Aug 24. doi: 10.1007/s12253-019-00726-w. [Epub ahead of print]

PMID:
31446607
2.

Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer.

Tőkés AM, Rusz O, Cserni G, Tóth E, Rubovszky G, Tőkés T, Vízkeleti L, Reiniger L, Kószó R, Kahán Z, Kulka J, Donia M, Vörös A, Szallasi Z.

Acta Oncol. 2019 Jul 4:1-9. doi: 10.1080/0284186X.2019.1633015. [Epub ahead of print]

PMID:
31271119
3.

Combined effect of chronic partial occlusion and orthostatic load on the saphenous vein network: A varicosity model in the rat.

Dörnyei G, Hetthéssy J, Patai B, Balogh F, Németi Á, Jäckel M, Tőkes A, Fees A, Varady Z, Monos E, Nádasy GL.

Phlebology. 2019 May 27:268355519852557. doi: 10.1177/0268355519852557. [Epub ahead of print]

PMID:
31132939
4.

Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations.

Kajáry K, Lengyel Z, Tőkés AM, Kulka J, Dank M, Tőkés T.

Pathol Oncol Res. 2019 Apr 3. doi: 10.1007/s12253-019-00641-0. [Epub ahead of print]

PMID:
30941738
5.

LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas.

Rusz O, Papp O, Vízkeleti L, Molnár BÁ, Bende KC, Lotz G, Ács B, Kahán Z, Székely T, Báthori Á, Szundi C, Kulka J, Szállási Z, Tőkés AM.

Cancer Chemother Pharmacol. 2018 Jul;82(1):139-147. doi: 10.1007/s00280-018-3602-z. Epub 2018 May 16.

PMID:
29770955
6.

Presence of cardiomyocytes exhibiting Purkinje-type morphology and prominent connexin45 immunoreactivity in the myocardial sleeves of cardiac veins.

Kugler S, Nagy N, Rácz G, Tőkés AM, Dorogi B, Nemeskéri Á.

Heart Rhythm. 2018 Feb;15(2):258-264. doi: 10.1016/j.hrthm.2017.09.044. Epub 2017 Oct 5.

PMID:
28987458
7.

PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.

Ács B, Madaras L, Tőkés AM, Kovács AK, Kovács E, Ozsvári-Vidákovich M, Karászi Á, Birtalan E, Dank M, Szász AM, Kulka J.

Breast. 2017 Oct;35:69-77. doi: 10.1016/j.breast.2017.06.013. Epub 2017 Jun 23.

PMID:
28651116
8.

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Jun 6;8:15759. doi: 10.1038/ncomms15759.

9.

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Apr 20;8:14944. doi: 10.1038/ncomms14944. Erratum in: Nat Commun. 2017 Jun 06;8:15759.

10.

Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer.

Ács B, Madaras L, Kovács KA, Micsik T, Tőkés AM, Győrffy B, Kulka J, Szász AM.

Pathol Oncol Res. 2018 Jan;24(1):115-127. doi: 10.1007/s12253-017-0220-8. Epub 2017 Apr 11.

PMID:
28401450
11.

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.

Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G, Tőkés T, Molnár BÁ, Molnár IA, Vári-Kakas S, Kulka J, Tőkés AM.

Diagn Pathol. 2017 Feb 21;12(1):20. doi: 10.1186/s13000-017-0608-5.

12.

Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter?

Ács B, Kulka J, Kovács KA, Teleki I, Tőkés AM, Meczker Á, Győrffy B, Madaras L, Krenács T, Szász AM.

Hum Pathol. 2017 Jul;65:31-40. doi: 10.1016/j.humpath.2017.01.011. Epub 2017 Feb 8.

PMID:
28188752
13.

Breast carcinoma subtypes show different patterns of metastatic behavior.

Molnár IA, Molnár BÁ, Vízkeleti L, Fekete K, Tamás J, Deák P, Szundi C, Székely B, Moldvay J, Vári-Kakas S, Szász MA, Ács B, Kulka J, Tőkés AM.

Virchows Arch. 2017 Mar;470(3):275-283. doi: 10.1007/s00428-017-2065-7. Epub 2017 Jan 19.

PMID:
28101678
14.

High pressure-low flow remodeling of the rat saphenous vein wall.

Hetthéssy JR, Tőkés AM, Kérész S, Balla P, Dörnyei G, Monos E, Nádasy GL.

Phlebology. 2018 Mar;33(2):128-137. doi: 10.1177/0268355516688984. Epub 2017 Jan 17.

PMID:
28094663
15.

Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients.

Szekely B, Nagy ZI, Farago Z, Kiss O, Lotz G, Kovacs KA, Madaras L, Udvarhelyi N, Dank M, Szentmartoni G, Baranyai Z, Harsanyi L, Tőkés AM, Timar J, Szasz AM, Kulka J.

Clin Exp Metastasis. 2017 Jan;34(1):103-113. doi: 10.1007/s10585-016-9830-x. Epub 2016 Nov 24.

PMID:
27885435
16.

Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO.

Breast Cancer Res Treat. 2016 Aug;159(1):199. No abstract available.

PMID:
27447877
17.

Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.

Szendrői A, Szász AM, Kardos M, Tőkés AM, Idan R, Szűcs M, Kulka J, Nyirády P, Szendrői M, Szállási Z, Győrffy B, Tímár J.

Oncotarget. 2016 Jul 5;7(27):42086-42098. doi: 10.18632/oncotarget.9669.

18.

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO.

Breast Cancer Res Treat. 2016 May;157(1):65-75. doi: 10.1007/s10549-016-3804-1. Epub 2016 Apr 26. Erratum in: Breast Cancer Res Treat. 2016 Aug;159(1):199.

19.
20.

Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based Study.

Kulka J, Székely B, Lukács LV, Kiss O, Tőkés AM, Vincze E, Turányi E, Fillinger J, Hanzély Z, Arató G, Szendrői M, Győrffy B, Szász AM.

J Histochem Cytochem. 2016 Apr;64(4):256-67. doi: 10.1369/0022155416639013.

21.

Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer.

Tőkés T, Tőkés AM, Szentmártoni G, Kiszner G, Madaras L, Kulka J, Krenács T, Dank M.

Virchows Arch. 2016 Jun;468(6):675-86. doi: 10.1007/s00428-016-1925-x. Epub 2016 Mar 30.

PMID:
27026269
22.

Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.

Tőkés T, Kajáry K, Szentmártoni G, Lengyel Z, Györke T, Torgyík L, Somlai K, Tőkés AM, Kulka J, Dank M.

Breast Cancer. 2017 Jan;24(1):137-146. doi: 10.1007/s12282-016-0685-4. Epub 2016 Mar 15.

PMID:
26979062
23.

[Clinico-pathologically focused breast cancer research].

Kulka J, Tõkés AM, Madaras L, Kovács A, Ács B, Illyés I, Kiss O, Székely B, Lotz G, Szász MA.

Magy Onkol. 2015 Dec;59(4):286-91. Epub 2015 Oct 12. Hungarian.

24.

BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.

Madaras L, Balint N, Gyorffy B, Tokes AM, Barshack I, Yosepovich A, Friedman E, Paluch-Shimon S, Zippel D, Baghy K, Timar J, Kovalszky I, Kulka J, Szasz AM.

Pathobiology. 2016;83(1):1-12. doi: 10.1159/000439135. Epub 2015 Nov 14.

25.

Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands.

Kiss O, Tőkés AM, Vranic S, Gatalica Z, Vass L, Udvarhelyi N, Szász AM, Kulka J.

Virchows Arch. 2015 Nov;467(5):551-62. doi: 10.1007/s00428-015-1827-3. Epub 2015 Aug 21.

PMID:
26293217
26.

Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.

Tőkés T, Szentmártoni G, Torgyík L, Kajáry K, Lengyel Z, Györke T, Molnár BÁ, Tőkés AM, Kulka J, Dank M.

Croat Med J. 2015 Apr;56(2):128-38.

27.

Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases.

Tökés AM, Szász AM, Geszti F, Lukács LV, Kenessey I, Turányi E, Meggyesházi N, Molnár IA, Fillinger J, Soltész I, Bálint K, Hanzély Z, Arató G, Szendröi M, Kulka J.

J Clin Pathol. 2015 Apr;68(4):274-82. doi: 10.1136/jclinpath-2014-202607. Epub 2015 Jan 16.

PMID:
25595275
28.

Breast- and salivary gland-derived adenoid cystic carcinomas: potential post-transcriptional divergencies. A pilot study based on miRNA expression profiling of four cases and review of the potential relevance of the findings.

Kiss O, Tőkés AM, Spisák S, Szilágyi A, Lippai N, Székely B, Szász AM, Kulka J.

Pathol Oncol Res. 2015 Jan;21(1):29-44. doi: 10.1007/s12253-014-9770-1. Epub 2014 Sep 21.

PMID:
25240490
29.

Comparison of passive and active biomechanical properties of human cervical and leg veins.

Gősi G, Monori-Kiss A, Nádasy G, Durkó A, Tőkés A, Monos E, Acsády G.

Int Angiol. 2014 Aug;33(4):348-56.

PMID:
25056166
30.

Lower-limb veins are thicker and vascular reactivity is decreased in a rat PCOS model: concomitant vitamin D3 treatment partially prevents these changes.

Várbíró S, Sára L, Antal P, Monori-Kiss A, Tőkés AM, Monos E, Benkő R, Csibi N, Szekeres M, Tarszabo R, Novak A, Paragi P, Nádasy GL.

Am J Physiol Heart Circ Physiol. 2014 Sep 15;307(6):H848-57. doi: 10.1152/ajpheart.01024.2013. Epub 2014 Jul 11.

31.

Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples.

Arvai K, Horváth P, Balla B, Tőkés AM, Tobiás B, Takács I, Nagy Z, Lakatos P, Kósa JP.

Fam Cancer. 2014 Dec;13(4):583-9. doi: 10.1007/s10689-014-9730-7.

PMID:
24853695
32.

In breast cancer patients sentinel lymph node metastasis characteristics predict further axillary involvement.

Illyes I, Tokes AM, Kovacs A, Szasz AM, Molnar BA, Molnar IA, Kaszas I, Baranyak Z, Laszlo Z, Kenessey I, Kulka J.

Virchows Arch. 2014 Jul;465(1):15-24. doi: 10.1007/s00428-014-1579-5. Epub 2014 May 9.

PMID:
24809673
33.

Clinicopathological features and prognosis of pregnancy associated breast cancer - a matched case control study.

Madaras L, Kovács KA, Szász AM, Kenessey I, Tőkés AM, Székely B, Baranyák Z, Kiss O, Dank M, Kulka J.

Pathol Oncol Res. 2014 Jul;20(3):581-90. doi: 10.1007/s12253-013-9735-9. Epub 2013 Dec 20.

PMID:
24357159
34.

[MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas].

Kiss O, Tőkés AM, Spisák S, Szilágyi A, Lippai N, Szász AM, Kulka J.

Orv Hetil. 2013 Jun 23;154(25):963-8. doi: 10.1556/OH.2013.29643. Hungarian.

PMID:
23774803
35.

Effects of vitamin D3 derivative--calcitriol on pharmacological reactivity of aortic rings in a rodent PCOS model.

Masszi G, Novak A, Tarszabo R, Horvath EM, Buday A, Ruisanchez E, Tokes AM, Sara L, Benko R, Nadasy GL, Revesz C, Hamar P, Benyó Z, Varbiro S.

Pharmacol Rep. 2013;65(2):476-83.

36.

Retrospective analysis of clinicopathological characteristics and family history data of early-onset breast cancer: a single-institutional study of Hungarian patients.

Madaras L, Baranyák Z, Kulka J, Szász AM, Kovács A, Lan PH, Székely B, Dank M, Nagy T, Kiss O, Harsányi L, Barbai T, Kenessey I, Tőkés AM.

Pathol Oncol Res. 2013 Oct;19(4):723-9. doi: 10.1007/s12253-013-9635-z. Epub 2013 May 26.

PMID:
23709114
37.

Endothelial relaxation mechanisms and nitrative stress are partly restored by Vitamin D3 therapy in a rat model of polycystic ovary syndrome.

Masszi G, Benko R, Csibi N, Horvath EM, Tokes AM, Novak A, Beres NJ, Tarszabo R, Buday A, Repas C, Bekesi G, Patocs A, Nadasy GL, Hamar P, Benyo Z, Varbiro S.

Life Sci. 2013 Aug 6;93(4):133-8. doi: 10.1016/j.lfs.2013.05.003. Epub 2013 May 14. Erratum in: Life Sci. 2014 Mar 28;100(1):73.

PMID:
23685132
38.

[Simplified, low-cost gene expression profiling for the prediction of outcome in breast cancer based on routine histologic specimens].

Szász AM, Ács B, Ágoston E, Sztupinszki Z, Tőkés AM, Szittya L, Székely B, Szendrői M, Li Q, Harsányi L, Tímár J, Szállási Z, Swanton C, Győrffy B, Kulka J.

Orv Hetil. 2013 Apr 21;154(16):627-32. doi: 10.1556/OH.2013.29590. Hungarian.

PMID:
23587542
39.

Reduced estradiol-induced vasodilation and poly-(ADP-ribose) polymerase (PARP) activity in the aortas of rats with experimental polycystic ovary syndrome (PCOS).

Masszi G, Horvath EM, Tarszabo R, Benko R, Novak A, Buday A, Tokes AM, Nadasy GL, Hamar P, Benyó Z, Varbiro S.

PLoS One. 2013;8(3):e55589. doi: 10.1371/journal.pone.0055589. Epub 2013 Mar 26. Erratum in: PLoS One. 2014;9(2):e91625.

40.

A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.

Szekely B, Iwamoto T, Szasz AM, Qi Y, Matsuoka J, Symmans WF, Tokes AM, Kulka J, Swanton C, Pusztai L.

Breast Cancer Res Treat. 2013 Apr;138(3):691-8. doi: 10.1007/s10549-013-2475-4. Epub 2013 Mar 17.

PMID:
23504136
41.

The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer.

Szász AM, Li Q, Eklund AC, Sztupinszki Z, Rowan A, Tőkés AM, Székely B, Kiss A, Szendrői M, Győrffy B, Szállási Z, Swanton C, Kulka J.

PLoS One. 2013;8(2):e56707. doi: 10.1371/journal.pone.0056707. Epub 2013 Feb 26.

42.

Arteriolar biomechanics in a rat polycystic ovary syndrome model - effects of parallel vitamin D3 treatment.

Sára L, Nádasy G, Antal P, Szekeres M, Monori-Kiss A, Horváth EM, Tőkés AM, Masszi G, Monos E, Várbíró S.

Acta Physiol Hung. 2012 Sep;99(3):279-88. doi: 10.1556/APhysiol.99.2012.3.5.

PMID:
22982716
43.

[Morphological and immunophenotypical heterogeneity in breast cancers of young and elderly women].

Madaras L, Szász MA, Baranyák Z, Tõkés AM, Szittya L, Lotz G, Székely B, Szentmártoni G, Dank M, Baranyai Z, Kulka J.

Magy Onkol. 2012 May;56(2):75-8. doi: MagyOnkol.2012.56.2.75. Epub 2012 Jan 17. Hungarian.

44.

Expression of tight junction molecules in breast carcinomas analysed by array PCR and immunohistochemistry.

Tőkés AM, Szász AM, Juhász E, Schaff Z, Harsányi L, Molnár IA, Baranyai Z, Besznyák I Jr, Zaránd A, Salamon F, Kulka J.

Pathol Oncol Res. 2012 Jul;18(3):593-606. doi: 10.1007/s12253-011-9481-9. Epub 2011 Dec 23.

PMID:
22193974
45.

Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer.

Szasz AM, Nemeth Z, Gyorffy B, Micsinai M, Krenacs T, Baranyai Z, Harsanyi L, Kiss A, Schaff Z, Tokes AM, Kulka J.

Cancer Sci. 2011 Dec;102(12):2248-54. doi: 10.1111/j.1349-7006.2011.02085.x. Epub 2011 Oct 12.

46.

Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis.

Szasz AM, Tokes AM, Micsinai M, Krenacs T, Jakab C, Lukacs L, Nemeth Z, Baranyai Z, Dede K, Madaras L, Kulka J.

Clin Exp Metastasis. 2011 Jan;28(1):55-63. doi: 10.1007/s10585-010-9357-5. Epub 2010 Oct 21.

PMID:
20963473
47.

[Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].

Kulka J, Tokés AM, Tóth AI, Szász AM, Farkas A, Borka K, Járay B, Székely E, Istók R, Lotz G, Madaras L, Korompay A, Harsányi L, László Z, Rusz Z, Molnár BA, Molnár IA, Kenessey I, Szentmártoni G, Székely B, Dank M.

Magy Onkol. 2009 Dec;53(4):335-43. doi: 10.1556/MOnkol.53.2009.4.2. Hungarian.

48.

beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression.

Szász AM, Nyirády P, Majoros A, Szendrõi A, Szûcs M, Székely E, Tõkés AM, Romics I, Kulka J.

BJU Int. 2010 Mar;105(5):716-22. doi: 10.1111/j.1464-410X.2009.08808.x. Epub 2009 Oct 10.

49.

Stromal matrix protein expression following preoperative systemic therapy in breast cancer.

Tokes AM, Szasz AM, Farkas A, Toth AI, Dank M, Harsanyi L, Molnar BA, Molnar IA, Laszlo Z, Rusz Z, Kulka J.

Clin Cancer Res. 2009 Jan 15;15(2):731-9. doi: 10.1158/1078-0432.CCR-08-1523.

50.

Expression of tight junction protein claudin-4 in basal-like breast carcinomas.

Kulka J, Szász AM, Németh Z, Madaras L, Schaff Z, Molnár IA, Tokés AM.

Pathol Oncol Res. 2009 Mar;15(1):59-64. doi: 10.1007/s12253-008-9089-x. Epub 2008 Aug 28.

PMID:
18752049

Supplemental Content

Support Center